Advancing Disease Treatment through Research

Each year, an estimated 55,000 to 60,000 bone marrow or umbilical cord blood transplants (also called hematopoietic cell transplants) are performed worldwide to treat patients with life-threatening diseases. [1] Due to advances in transplantation, long-term experience and ongoing clinical trials, doctors can now recommend transplant to more patients than ever before. The list of diseases for which a transplant is a standard treatment option continues to grow.

Below is a list of diseases for which a transplant — either autologous (using the patient’s own cells) or allogeneic (using a donor’s cells) — may be a treatment. The list includes diagnoses for which transplant is a standard treatment as well as those for which it is a newer option.

Diseases treatable

Leukemias and lymphomas, including:

Acute myelogenous leukemia
Acute lymphoblastic leukemia
Chronic myelogenous leukemia
Chronic lymphocytic leukemia
Juvenile myelomonocytic leukemia
Hodgkin lymphoma
Non-Hodgkin lymphoma

Learn more about research advancing treatments for acute leukemias

Multiple myeloma and other plasma cell disorders

Severe aplastic anemia and other marrow failure states, including:

Severe aplastic anemia -- learn more about research advancing treatment for severe aplastic anemia in children
Fanconi anemia
Paroxysmal nocturnal hemoglobinuria (PNH)
Pure red cell aplasia
Amegakaryocytosis / congenital thrombocytopenia

SCID and other inherited immune system disorders, including:

Severe combined immunodeficiency (SCID, all sub-types)
Wiskott-Aldrich syndrome

Hemoglobinopathies, including:

Beta thalassemia major
Sickle cell disease

Hurler's syndrome and other inherited metabolic disorders, including:

Hurler's syndrome (MPS-IH)
Adrenoleukodystrophy
Metachromatic leukodystrophy

Myelodysplastic and myeloproliferative disorders, including:

Refractory anemia (all types)
Chronic myelomonocytic leukemia
Agnogenic myeloid metaplasia (myelofibrosis)

Learn more about research advancing treatment for myelodysplastic disorders

Familial erythrophagocytic lymphohistiocytosis and other histiocytic disorders

Other malignancies

Fine-tuning transplant for specific diseases

The most effective timing for transplant, pre-transplant conditioning regimen (chemotherapy and/or radiation), cell source and post-transplant treatment options vary by disease. Research targeted to specific diseases is ongoing and continues to improve patients’ survival rates and quality of life after transplant.

One way your funding helps

Be The Match Foundation^® understands investing in cutting-edge research is critical to serving more patients in need of a transplant. Funding clinical and observational studies is costly. But the data gleaned from in-depth patient tracking is so vital to refining therapies, improving survival rates and discovering the next generation of transplant care that your funds are needed here.

You have the power to heal. Please give to support research.